Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1550-1558

  Hongy, Zhenya ^a   Xiaoy, Min ^a   Yang, Yang ^a   Han, Zhiqiang ^a   Cao, Yang ^a   Li, Chunrui ^a   Wu, Ying ^a   Gong, Quan ^a   Zhou, Xiaoxi ^a   Xu, Danmei ^a   Meng, Li ^a   Ma, Ding ^a   Zhou, Jianfeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC DISULFIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROPIDIUM IODIDE 103; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SCID MOUSE; STEM CELL; UMBILICAL CORD BLOOD;

ANIMALS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG SYNERGISM; FURANS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; SULFIDES; TOR SERINE-THREONINE KINASES;

EID: 80053138926     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr176     Document Type: Article

References (32)

1. Emadi,A. et al. (2010) Arsenic trioxide-an old drug rediscovered. Blood Rev., 24, 191-199.
2. Nowak,D. et al. (2009) Differentiation therapy of leukemia: 3 decades of development. Blood, 113, 3655-3665.
3. Rowley,J.D. et al. (1977) 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet, 1, 549-550.
4. Tatham,M.H. et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol., 10, 507-509.
5. Rousselot,P. et al. (2004) A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia, 18, 1518-1521.
6. Qazilbash,M.H. et al. (2008) Arsenic trioxide with ascorbic acid and highdose melphalan: results of a phase II randomized trial. Biol. Blood Marrow Transplant., 14, 1401-1407.
7. Berenson,J.R. et al. (2007) A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res., 13, 1762-1768.
8. Roboz,G.J. et al. (2008) Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer, 113, 2504-2511.
9. Rojewski,M.T. et al. (2002) Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br. J. Haematol., 116, 555-563.
10. Ito,K. et al. (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 453, 1072-1079.
11. Zhang,X.W. et al. (2010) Arsenic trioxide controls the fate of the PMLRARa oncoprotein by directly binding PML. Science, 328, 240-243.
12. Kapahi,P. et al. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem., 275, 3062-3066.
13. Pelicano,H. et al. (2006) Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia, 20, 610-619.
14. Ramos,A.M. et al. (2005) Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood, 105, 4013-4020.
15. Lu,D.P. et al. (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood, 99, 3136-3143.
16. West,K.A. et al. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 5, 234-248.
17. Franke,T.F. et al. (2003) PI3K/Akt and apoptosis: size matters. Oncogene, 22, 8983-8998.
18. Guzman,M.L. et al. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301-2307.
19. Xu,Q. et al. (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 102, 972-980.
20. Yilmaz,O.H. et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 441, 475-482.
21. Guzman,M.L. et al. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl Acad. Sci. USA., 99, 16220-16225.
22. Chou,T.C. et al. (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem., 115, 207-216.
23. Jin,L. et al. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med., 12, 1167-1174.
24. Wilson,A. et al. (2008) Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell, 135, 1118-1129.
25. Han,Z. et al. (2009) A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis, 30, 2014-2022.
26. Hayashi,T. et al. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther., 1, 851-860.
27. Fan,Q.W. et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer. Cell, 9, 341-349.
28. Petrie,K. et al. (2009) Differentiation therapy of acute myeloid leukemia: past, present and future. Curr. Opin. Hematol., 16, 84-91.
29. Ciardiello,F. et al. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med., 358, 1160-1174.
30. Endersby,R. et al. (2008) PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene, 27, 5416-5430.
31. Qiu,J. (2007) 'Back to the future' for Chinese herbal medicines. Nat. Rev. Drug Discov., 6, 506-507.
32. Wicha,M.S. et al. (2006) Cancer stem cells: an old idea-a paradigm shift. Cancer Res., 66, 1883-1890.